Radiopharmaceutical developer Mallinckrodt Medical said that itwill begin sales in Sweden of TechneScan Q12, a technetium-basedcardiac imaging agent, following approval of the agent by Sweden'shealth authorities. Sweden is the first country in the
Radiopharmaceutical developer Mallinckrodt Medical said that it
will begin sales in Sweden of TechneScan Q12, a technetium-based
cardiac imaging agent, following approval of the agent by Sweden's
health authorities. Sweden is the first country in the European
Union to approve TechneScan, and certifications in other European
nations are expected. St. Louis-based Mallinckrodt filed a new
drug application for the product in the U.S. in 1994.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.